

## ASX Announcement (ASX: HLS)

ASX Limited  
Market Announcements Office  
Exchange Centre  
Level 4, 20 Bridge Street  
Sydney NSW 2000



ACN 064 530 516  
REGISTERED OFFICE:  
LEVEL 22  
161 Castlereagh Street  
SYDNEY NSW 2000  
TEL: +61 2 9432 9400  
FAX: +61 2 9432 9447

1 May 2025

### Completion of Sale of Lumus Imaging to Affinity Equity Partners

Healius Limited (“**Healius**”) (ASX: HLS) today announces the successful completion of the sale of Lumus Imaging (“**Lumus**”) to funds managed by Affinity Equity Partners (“**Affinity**”).

Healius has received cash proceeds of \$822 million, which represents \$965 million enterprise value adjusted for repayment of equipment leases and closing adjustments<sup>1</sup>. As previously announced, net proceeds are expected to be in excess of \$800 million after all transaction fees, separation costs and other fees.

As previously announced, the company intends to pay a Special Dividend of approximately \$300 million or 41.3 cents per share fully franked. Further details will be provided in the week commencing 5 May 2025.

Paul Anderson, Managing Director and Chief Executive Officer of Healius, said “The sale of Lumus resets Healius’ balance sheet and allows the business to focus on executing our pathology strategy by providing better services for our patients and referrers. With the simplification of our operations, we will also be in a position to streamline the corporate cost base.”

“On behalf of Healius, I would like to express my appreciation for the contribution of Lumus’ Radiologists, staff and management team led by Dr Phil Lucas. We wish them all the best as a stand-alone entity under the ownership of Affinity.”

To support the separation and ensure a smooth transition for both Lumus Imaging and its patients, Healius will continue to provide Lumus with a range of transitional services, including certain IT services on commercial arm’s-length terms for a period of up to eighteen months from completion.

This announcement is authorised for release to the ASX by the Board of Directors of Healius.

**ENDS**

For further information contact:

Sharon Ng  
Head of FP&A and Investor Relations

Amy Liu  
FP&A and Investor Relations Manager

Mobile: +61 466 023 858

*For over 30 years Healius has been one of Australia’s leading healthcare companies, committed to supporting quality, affordable and accessible healthcare for all Australians. Through its unique footprint of centres and its 8,500+ employees, Healius provides Australia-wide specialty pathology services to consumers and their referring practitioners.*

<sup>1</sup> Closing adjustments relate primarily to working capital and capital expenditure movements. The difference between net transaction proceeds of \$835 million in the 23 September 2024 ASX announcement and \$822 million received on 1 May 2025 relates to certain liabilities transferred to the buyer which were previously to be paid by Healius and movements in working capital. Net proceeds to the company are unchanged as set out above.